These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 31793850)

  • 1. Initial M Staging of Rectal Cancer: FDG PET/MRI with a Hepatocyte-specific Contrast Agent versus Contrast-enhanced CT.
    Yoon JH; Lee JM; Chang W; Kang HJ; Bandos A; Lim HJ; Kang SY; Kang KW; Ryoo SB; Jeong SY; Park KJ
    Radiology; 2020 Feb; 294(2):310-319. PubMed ID: 31793850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation.
    Rappeport ED; Loft A; Berthelsen AK; von der Recke P; Larsen PN; Mogensen AM; Wettergren A; Rasmussen A; Hillingsoe J; Kirkegaard P; Thomsen C
    Acta Radiol; 2007 May; 48(4):369-78. PubMed ID: 17453514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results.
    Bruckmann NM; Kirchner J; Morawitz J; Umutlu L; Herrmann K; Bittner AK; Hoffmann O; Mohrmann S; Ingenwerth M; Schaarschmidt BM; Li Y; Stang A; Antoch G; Sawicki LM; Buchbender C
    PLoS One; 2021; 16(12):e0260804. PubMed ID: 34855886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic accuracy of FDG-PET/MRI versus pelvic MRI and thoracic and abdominal CT for detecting synchronous distant metastases in rectal cancer patients.
    Queiroz MA; Ortega CD; Ferreira FR; Nahas SC; Cerri GG; Buchpiguel CA
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):186-195. PubMed ID: 32561971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse features on rectal MRI identify a high-risk group that may benefit from more intensive preoperative staging and treatment.
    Hunter CJ; Garant A; Vuong T; Artho G; Lisbona R; Tekkis P; Abulafi M; Brown G
    Ann Surg Oncol; 2012 Apr; 19(4):1199-205. PubMed ID: 21913017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of
    Hotta M; Minamimoto R; Yano H; Gohda Y; Shuno Y
    Cancer Imaging; 2018 Jan; 18(1):4. PubMed ID: 29378659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/MRI and PET/CT hybrid imaging of rectal cancer - description and initial observations from the RECTOPET (REctal Cancer trial on PET/MRI/CT) study.
    Rutegård MK; Båtsman M; Axelsson J; Brynolfsson P; Brännström F; Rutegård J; Ljuslinder I; Blomqvist L; Palmqvist R; Rutegård M; Riklund K
    Cancer Imaging; 2019 Jul; 19(1):52. PubMed ID: 31337428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer.
    Gearhart SL; Frassica D; Rosen R; Choti M; Schulick R; Wahl R
    Ann Surg Oncol; 2006 Mar; 13(3):397-404. PubMed ID: 16485158
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Gassert FG; Rübenthaler J; Cyran CC; Rink JS; Schwarze V; Luitjens J; Gassert FT; Makowski MR; Schoenberg SO; Mayerhoefer ME; Tamandl D; Froelich MF
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3268-3276. PubMed ID: 33686457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the primary staging of rectal cancer.
    Ozis SE; Soydal C; Akyol C; Can N; Kucuk ON; Yagcı C; Erkek AB; Kuzu MA
    World J Surg Oncol; 2014 Feb; 12():26. PubMed ID: 24484935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study.
    Paspulati RM; Partovi S; Herrmann KA; Krishnamurthi S; Delaney CP; Nguyen NC
    Abdom Imaging; 2015 Aug; 40(6):1415-25. PubMed ID: 26112492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of FDG Positron Emission Tomography/Contrast--Enhanced Computed Tomography in Preoperative Staging and Postoperative Follow-up in Rectal Cancer Surgery.
    Omarov N; Uymaz DS; Kulle CB; Ozkan ZG; Azamat S; Keskin M; Bulut MT
    Pol Przegl Chir; 2022 Feb; 94(6):10-16. PubMed ID: 36468505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron-emission tomography/computed tomography (PET/CT) in the initial staging of primary rectal cancer.
    Eglinton T; Luck A; Bartholomeusz D; Varghese R; Lawrence M
    Colorectal Dis; 2010 Jul; 12(7):667-73. PubMed ID: 19486092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT--initial clinical experience.
    Squillaci E; Manenti G; Mancino S; Cicciò C; Calabria F; Danieli R; Schillaci O; Simonetti G
    Abdom Imaging; 2008; 33(6):676-88. PubMed ID: 18373114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
    Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
    Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of fusion of PET and MRI for staging of endometrial cancer: comparison with ¹⁸F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI.
    Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Takahashi S; Ebina Y; Miyahara Y; Yamada H; Sugimura K
    Eur J Radiol; 2013 Oct; 82(10):1672-6. PubMed ID: 23727380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.